Editorial: Mycobacterial Glycolipids—Role in Immunomodulation and Targets for Vaccine Development

1 Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 2 Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre national de la recherche scientifique (CNRS), Université Paul Sabatier, Toulouse, France, 3 Leicester Tuberculosis Research Group (LTBRG), Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom, 4 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, 5 ICVS/Biomaterials, Biodegradables and Biomimetics (3B’s), Portugal (PT) Government Associate Laboratory, Braga, Portugal

[1]  Nazim Madhavji,et al.  Organization , 2020, WER.

[2]  F. Berti,et al.  Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. , 2020, Current opinion in immunology.

[3]  T. Scriba,et al.  Moving tuberculosis vaccines from theory to practice , 2019, Nature Reviews Immunology.

[4]  B. Hamasur,et al.  Biomarkers for tuberculosis: the case for lipoarabinomannan , 2019, ERJ Open Research.

[5]  S. Suliman,et al.  CD1: From Molecules to Diseases , 2017, F1000Research.

[6]  C. Demangel,et al.  Pathogenic and immunosuppressive properties of mycobacterial phenolic glycolipids. , 2017, Biochimie.

[7]  S. Swaminathan,et al.  Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions , 2016, PLoS medicine.

[8]  M. Gilleron,et al.  Glycolipid Presentation by CD1 , 2015 .

[9]  J. Nigou,et al.  Manipulation of the endocytic pathway and phagocyte functions by Mycobacterium tuberculosis lipoarabinomannan , 2015, Front. Cell. Infect. Microbiol..

[10]  I. Orme,et al.  The balance between protective and pathogenic immune responses in the TB-infected lung , 2014, Nature Immunology.

[11]  D. Minnikin,et al.  Lipids of Clinically Significant Mycobacteria , 2020, Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids.

[12]  S. Yamasaki,et al.  Recognition of Mycobacterial Lipids by Immune Receptors. , 2017, Trends in immunology.

[13]  Emilie Layre.  LIPID ADJUVANTS AND ANTIGENS EMBEDDED IN THE MYCOBACTERIAL CELL ENVELOPE , 2014 .

[14]  K. Timmis.  Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids , 2010 .

[15]  G. Puzo,et al.  6 Structure, Biosynthesis, and Activities of the Phosphatidyl-myo-Inositol-Based Lipoglycans , 2008 .